North East and North Cumbria
ICS Formulary
 
back
6 Endocrine system
06-01-02-03 GLP1 agonists

Dulaglutide Trulicity®
Formulary
  • 0.75mg, 1.5mg, 3mg and 4.5mg prefilled syringes
    • Approved for use in patients who require once-weekly GLP-1 receptor agonist therapy. 
    • This has replaced once-weekly exenatide. Existing patients can continue to receive exenatide until reviewed by a specialist

 
Link  National Patient Safety Alert - Shortage of GLP-1 receptor agonists (GLP-1 RA) update
Link  NICE NG18: Diabetes (type 1 and type 2) in children and young people: diagnosis and management

Green View adult BNF  View SPC online  View childrens BNF
Exenatide
Formulary
  • 5 microgram and 10 microgram per dose are prefilled injection pens containing a 250microgram/ml solution for subcutaneous injection.
    • Only approved for use in accordance with NICE guidance Treatment must be initiated by a consultant diabetologist and use is limited to overweight patients with type 2 diabetes in line with NICE guidelines.
  • 2.5mg/0.85ml prolonged-release suspension for injection
    • temporarily approved due to supply issues with semaglutide and dulaglutide (please refer to linked advice below)

 
Link  EXENATIDE (Byetta®) - Information for Primary Care
Link  National Patient Safety Alert - Shortage of GLP-1 receptor agonists (GLP-1 RA) update

Green View adult BNF  View SPC online  View childrens BNF
Lixisenatide
Formulary
Link  National Patient Safety Alert - Shortage of GLP-1 receptor agonists (GLP-1 RA) update

Green View adult BNF  View SPC online  View childrens BNF
Semaglutide
Formulary
  • 0.25mg/0.19mL, 0.5mg/0.37mL and 1mg/0.7mL solution for injection pre-filled pen (Ozempic®)
    • Approved for the treatment of type 2 diabetes in patients who require an intensification in treatment
  • 3mg, 7mg & 14mg tablets (Rybelsus®) - BLACK TRIANGLE
    • Approved as an option for patients with type 2 diabetes mellitus who require intensification of treatment, if use of a glucagon-like peptide 1 receptor agonist (GLP1RA) is clinically appropriate, in line with licensing and relevant guidance, and if an oral option is preferred.
  • 0.25mg/0.37ml, 0.5mg/0.37ml, 1mg/0.75ml, 1.7mg/0.75ml & 2.4mg/0.75ml solution for injection pre-filled pens (Wegovy®) Red
    • Approved for managing overweight and obesity in line with NICE guidance within a specialist weight management service (including but not limited to tiers 3 and 4)
    • Also available via NHSE pilot sites involving primary care

 
Link  National Patient Safety Alert - Shortage of GLP-1 receptor agonists (GLP-1 RA) update
Link  NICE TA875: Semaglutide for managing overweight and obesity
Link  NTAG Treatment Appraisal: Oral semaglutide for the treatment of type 2 diabetes mellitus.

Green View adult BNF  View SPC online  View childrens BNF
Tirzepatide Mounjaro®
Formulary
  • 2.5mg/0.6ml  & 5mg/0.6ml solution for injection (pre-filled pens)
  • Approved for treating type 2 diabetes in line with NICE
Link  NICE TA924: Tirzepatide for treating type 2 diabetes

Green View adult BNF  View SPC online  View childrens BNF
Liraglutide
Formulary
  • Victoza® Green
    • Approved for the treatment of type 2 diabetes mellitus in accordance with NICE guidance   
  •  Saxenda®Red
    • Approved as an option for managing overweight and obesity alongside a reduced-calorie diet and increased physical activity in adults in line with NICE and providing: 
      • it is prescribed in secondary care by a specialist multidisciplinary tier 3 weight management service; and
      • the company provides it according to the commercial arrangement 
Link  National Patient Safety Alert - Shortage of GLP-1 receptor agonists (GLP-1 RA) update
Link  NICE NG18: Diabetes (type 1 and type 2) in children and young people: diagnosis and management
Link  NICE NG28: Type 2 diabetes in adults: management
Link  NICE TA664: Liraglutide for managing overweight and obesity

View adult BNF  View SPC online  View childrens BNF